18342-97-7

Basic information

• Product Name: 3-Hydroxypyridine-4-carboxylic acid ethyl ester
• Synonyms: 3-Hydroxypyridine-4-carboxylic acid ethyl ester;Ethyl 3-hydroxyisonicotinate;4-Pyridinecarboxylic acid, 3-hydroxy-, ethyl ester;Ethyl 3-hydroxypyridine-4-carboxylate;Ethyl 3-hydroxypyridine-4-carboxylate, 4-(Ethoxycarbonyl)-3-hydroxypyridine;3-Hydroxy-isonicotinic acid ethyl ester
• CAS NO: 18342-97-7
• Molecular Formula: C8H9NO3
• Molecular Weight: 167.16196
• Product Categories: pharmacetical
• Mol File: 18342-97-7.mol

Chemical Properties

• Melting Point: 35 °C
• Boiling Point: 321.943 °C at 760 mmHg
• Flash Point: 148.506 °C
• Appearance: /
• Density: 1.234 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: 2-8°C
• PKA: 7.05±0.10(Predicted)
• CAS DataBase Reference: 3-Hydroxypyridine-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxypyridine-4-carboxylic acid ethyl ester(18342-97-7)
• EPA Substance Registry System: 3-Hydroxypyridine-4-carboxylic acid ethyl ester(18342-97-7)

Safety Data

• Hazard Codes: Xi
• Statements: 41-22
• Safety Statements: 26-39-36/37
• Hazardous Substances Data: 18342-97-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellow to light brown powder

InChI:InChI=1/C8H9NO3/c1-2-12-8(11)6-3-4-9-5-7(6)10/h3-5,10H,2H2,1H3

Upstream product

• 141-52-6 sodium ethanolate 
• 10128-71-9 3-hydroxyisonicotinic acid 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 4664-01-1 3,4-pyridinedicarboximide 
• 14208-83-4 ethyl 3-aminopyridine-4-carboxylate 
• 64-17-5 ethanol 

Downstream Products

• 1454284-57-1 furo[2,3-c]pyridine-2-carboxylic acid 4-(tetrahydropyran-4-ylsulfamoyl)benzylamide 
• 1454284-75-3 N-(4-(6-methylpyridin-3-ylsulfonyl)benzyl)furo[2.3-c]pyridine-2-carboxamide 
• 1454250-96-4 (R)-N-([5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-yl]methyl)furo[2,3-c]pyridin-2-carboxamide 
• 1454250-97-5 (S)-N-([5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-yl]methyl)furo[2,3-c]pyridin-2-carboxamide 
• 1454250-93-1 N-([5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-yl]methyl)furo[2,3-c]pyridin-2-carboxamide 
• 1454250-90-8 furo[2,3-c]pyridin-2-carboxylic acid [5-(3-trifluoromethylbenzenesulfonyl)pyridin-2-ylmethyl]amide 
• 18343-02-7 Ethyl 2-(4-Ethoxycarbonyl-3-pyridyloxy) acetate 
• 1448536-37-5 N-{[4-(piperidine-1-sulfonyl)phenyl]methyl}furo[2,3-c]pyridine-2-carboxamide 
• 1453175-46-6 C₂₄H₂₉N₃O₃S 
• 1453175-45-5 C₂₄H₂₉N₃O₃S 
• 1453176-79-8 4-{[(furo[2,3-c]pyridine-2-carbonyl)-amino]-methyl}-benzenesulfonyl chloride 
• 1453176-78-7 furo[2,3-c]pyridine-2-carboxylic acid benzylamide 
• 465531-08-2 furo[2,3-c]pyridine-2-carbonyl chloride 
• 1453174-07-6 N-[[4-[(1-tetrahydropyran-4-yl-4-piperidyl)sulfonyl]phenyl]methyl]furo[2,3-c]pyridine-2-carboxamide 

Relevant articles and documents

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

There is provided compounds of formula I, (I) wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES

Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.

AMIDO-BENZYL SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat

ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES

The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,

AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Raf inhibitor compounds and methods of use thereof

Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.